Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Frequently asked questions
What sector does Adverum Biotechnologies Inc (AVU) operate in?
Adverum Biotechnologies Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Adverum Biotechnologies Inc (AVU) current stock price?
As of the latest data, Adverum Biotechnologies Inc stock price is €0.54, with a previous close of €0.53. Adverum Biotechnologies Inc gained €0.01 in the last trading session, representing a 1.13% increase.
What is Adverum Biotechnologies Inc (AVU) current market capitalization?
Adverum Biotechnologies Inc market cap is approximately 111.62 million.
What is Adverum Biotechnologies Inc (AVU) Earnings Per Share (EPS)?
The trailing EPS is -€10.68, and the forward EPS is -€1.28.
Does Adverum Biotechnologies Inc (AVU) pay dividends?
No. Adverum Biotechnologies Inc does not pay a dividend.
What is Adverum Biotechnologies Inc (AVU) beta (volatility) score?
Adverum Biotechnologies Inc has a beta of 0.873, meaning its volatility is roughly in line with the market.
